stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Revenue
Palvella Therapeutics, Inc.'s revenue for fiscal 2022 was $25.9M, down 17.6% from $31.4M in fiscal 2021. Over the twelve months to 31 March 2024 it was $41.6M. Over the past ten years it has ranged from $2.9M (fiscal 2015) to $46.3M (fiscal 2019); the current reading is higher than 50% of that period. Palvella Therapeutics, Inc. ranks 137th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2022 | $25.9M | (17.56%) |
| FY2021 | $31.4M | 7.14% |
| FY2020 | $29.3M | (36.64%) |
| FY2019 | $46.3M | 59.03% |
| FY2018 | $29.1M | 15.14% |
| FY2017 | $25.3M | 333.46% |
| FY2016 | $5.8M | 98.88% |
| FY2015 | $2.9M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Mar 2024 | $53.0K | (99.73%) |
| Sep 2023 | $19.5M | (2.67%) |
| Jun 2023 | $20.1M | 935.90% |
| Mar 2023 | $1.9M | (66.88%) |
| 32 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| ADMA ADMA Biologics Inc compare | $519.2M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $321.7M |
| PVLA Palvella Therapeutics, Inc. | $41.6M |
| IMNM Immunome, Inc. compare | $12.6M |
| CLDX Celldex Therapeutics, Inc. compare | $887.0K |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PVLA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement